论文部分内容阅读
目的观察伏立康唑治疗儿童血液病合并侵袭性肺曲霉菌感染(IPA)的临床疗效及安全性。方法回顾性分析医院2009年2月-2011年7月血液病伴发侵袭性肺曲霉菌感染住院患儿10例,所有患儿均经CT检查和GM试验临床诊断;伏立康唑针每次7mg/kg,静脉滴注,1次/12h,10～14d后改用伏立康唑片剂,剂量不变,口服1次/12h,总疗程4～8周;根据临床疗效标准,综合评价该药物的疗效和安全性。结果 10例患儿中,9例治疗有效,总有效率为90.0%,治疗有效的9例患儿从症状及体征上判定临床有效的时间为2～5d;伏立康唑治疗过程中两例发生轻微不良反应,不良反应发生率20.0%。结论伏立康唑口服和静脉给药均有很好的抗真菌活性,可作为儿童血液病伴发肺曲霉菌感染的一线用药,高效而安全。
Objective To observe the clinical efficacy and safety of voriconazole in the treatment of hematologic disease and invasive pulmonary aspergillosis (IPA) in children. Methods A retrospective analysis of 10 hospitalized patients with blood diseases associated with invasive pulmonary aspergillosis in the hospital from February 2009 to July 2011 was performed. All children were diagnosed by CT and GM tests. Voriconazole needles of 7 mg / kg , Intravenous infusion, once / 12h, 10 ~ 14d after the switch to voriconazole tablets, the same dose, oral 1 / 12h, the total course of 4 to 8 weeks; according to clinical efficacy criteria, the comprehensive evaluation of the efficacy and safety of the drug Sex. Results Of the 10 children, 9 were effective and the total effective rate was 90.0%. Nine children with effective treatment were clinically effective from 2 to 5 days on symptom and physical sign. Two cases occurred slight malnutrition during voriconazole treatment Response, the incidence of adverse reactions 20.0%. Conclusion Voriconazole has good antifungal activity both orally and intravenously. It can be used as a first-line medication for children with hematological diseases associated with pulmonary aspergillosis, which is safe and effective.